# Acadia Pharmaceuticals Stock Plummets After Clinical Failure

> Acadia Pharmaceuticals shares drop 8.6% after remlifanserin trial misses primary endpoint
- Title: Acadia Pharmaceuticals Stock Plummets After Clinical Failure
- Summary: Acadia Pharmaceuticals shares drop 8.6% after remlifanserin trial misses primary endpoint Remlifanserin clinical trial failure impacts Acadia's pipeline…
- Keywords: acadia, remlifanserin, clinical trial, stock price, biotech, pipeline expansion, clinical endpoint, Pharmaceuticals, Stock, Plummets, Clinical, Failure
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/acadia-pharmaceuticals-acad-drops-8-6-to-23-25
- Author: AlphaStreet Newsdesk
- Published: 2026-09-24T14:37:51+00:00
- Read time: 1 min
- Topics: acadia, remlifanserin, clinical trial, stock price, biotech, pipeline expansion, clinical endpoint
## Stock Tumbles 8.6%
ACADIA Pharmaceuticals shares dropped 8.6% Thursday to close at $23.25 after its remlifanserin clinical study failed to meet its primary endpoint.
## Clinical Trial Misses Goal
The company's remlifanserin, an investigational therapy, missed its main clinical trial goal, causing a significant setback for the biotech's pipeline expansion.
## Pre-Market Drop
Shares initially fell 10% in pre-market trading before closing down 8.6% after the news.
## Market Reaction
Trading volume reached 2.0 million shares as investors reassessed Acadia's development portfolio after the clinical failure.
## Pipeline Impact
The setback raises questions about Acadia's pipeline depth beyond its existing commercial products and future development strategies.
## Investor Concerns
Investors demand clearer paths to profitability and diversified revenue streams as Acadia navigates the clinical setback.
## Key takeaway

Remlifanserin clinical trial failure impacts Acadia's pipeline expansion and stock price